General Information

  IBMS Collective   Membership   Societies

  IBMS Affiliated   Societies

  IBMS Corporate   Partners Program

  IBMS Corporate   Partners

IBMS Corporate Partners

The International Bone and Mineral Society gratefully acknowledges the support of its 2007 partners:

The Alliance for Better Bone Health | Amgen | Chugai Pharmaceutical
GSK
| A Joint Force in Osteoporosis | Lilly
Merck | Novartis | Nycomed
Pfizer | Roche | Servier | Teijin | Wyeth

2007 Corporate Members

 

 

Information about Amgen Inc. is available at .

 

Chugai Pharmaceutical aspires for development of innovative drugs by integrating cutting-edge technologies into its unique drug discovery infrastructure. Funneling resources into prescription drugs, Chugai is pursuing research and development of antibody drug-centered biopharmaceuticals in five franchises; cancer, renal, cardiovascular, bone/joint, and transplantation/immunology/infectious diseases while actively working on the traditional chemical cynthesis drug discovery. Based on high ethical and moral standards for a life science enterprise, Chugai, with its Patient-First philosophy, is committed to contributing to society by developing innovative drugs enabling higher patients' QOL and better lives.

Additional information about Chugai is available at .

 

 

Eli Lilly and Company is a leading, innovation-driven corporation committed to developing a growing portfolio of best-in-class and first-in-class pharmaceutical products that help people live longer, healthier and more active lives. Lilly products treat depression, schizophrenia, attention-deficit hyperactivity disorder, diabetes, osteoporosis and many other conditions. We are committed to providing answers that matter - through medicines and information - for some of the world's most urgent medical needs.

Additional information about Lilly is available at .

Information about GSK is available at .

Merck, Sharp, and Dohme, Inc. (MSD) is a global, research-driven pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human health products. MSD, the manufacturer of FOSAMAX® (alendronate sodium), is a leader in osteoporosis research and treatment.

Additional information about MSD is available at .

 

 

Information about Novartis is available at .

Nycomed is a European pharmaceutical company. Rapidly expanding, Nycomed now operates in 19 European countries including Russia / CIS. We provide hospital/specialist products throughout Europe and GP & OTC products in selected markets. Within the field of osteoporosis, Nycomed is currently partnering with NPS pharmaceuticals on the development of full-length PTH (1-84) which stimulates growth of structurally-normal bone lost to the disease. This product is expected to further strengthen Nycomed’s existing osteoporosis position built through its Nycomed Calcium & Vitamin D3 portfolio.

If you want to learn more about us please visit our website:

Pfizer Inc discovers, develops, manufactures and markets leading prescription medicines, for humans and animals, and many of the world’s best-known consumer products. Pfizer Global Research and Development (PGRD) is the R&D division of Pfizer Inc. PGRD, the world’s largest private biomedical research organization, is headquartered in New London, Connecticut and has over 160 research projects in the following areas: antibacterials, antivirals, antifungals, arthritis, allergy and respiratory diseases, atherosclerosis, cardiovascular diseases, cancer, diabetes, gastrointestinal diseases, immunological diseases, metabolic diseases, neurodegenerative diseases, obesity, opthamological diseases, osteoporosis, pain research, psychotherapeutic research and sexual health/urology.

Additional information about Pfizer is available at .

Roche's Pharmaceuticals Division discovers, develops, manufactures and markets prescription drugs for the following therapeutic areas: osteoporosis, central nervous system, infectious diseases, oncology, virology, cardiovascular diseases, inflammatory and autoimmune diseases, dermatology, metabolic disorders and respiratory diseases. The division also plays an active role in the field of self-medication, where Roche Consumer Health is a market leader in many countries around the world. It is Roche's mission to provide innovative medicines that address currently unmet medical needs or improve on existing therapies.

Additional information about Roche is available at .

Servier is a leading French private pharmaceutical company with a worldwide consolidated turnover of 2.2 billion euros. Servier is both the largest and the fastest-growing independent pharmaceutical group, in France. Internationally, Servier is present in 140 countries, with 80% of its total sales coming from overseas. Servier has a major commitment to R&D, as more than 25% of total turnover is reinvested in R&D. Servier's main areas of therapeutic research are: cardiovascular disorders, metabolic diseases such as diabetes, neuropsychiatric diseases, cancer, respiratory diseases, and osteoporosis.

Servier has discovered and developed Protelos for the treatment of postmenopausal osteoporosis, the first treatment to rebalance bone turnover in favor of formation. Protelos has recently received its marketing authorization in Europe and is licensed for the treatment of postmenopausal osteoporosis to reduce the risk of hip and vertebral fractures. It will be available soon for prescription.

Additional information about Servier and Protelos is available at .

 

 

Information about Teijin is available at

 

Wyeth Pharmaceuticals is a major research-oriented pharmaceutical company with leading products in the areas of women’s health care, cardiovascular disease therapies, central nervous system drugs, musculosketetal therapies, infectious disease, hemophilia, oncology, and vaccines. As a world leader in women’s health care, the company is committed to women through ongoing research efforts and patient education programs.

Additional information about Wyeth is available at .

2007 BoneKEy Sponsors

 

 

Information about Amgen Inc. is available at .

 

Information about Procter & Gamble Pharaceuticals is available at .
Information about Aventis Pharma is available at .

 

 

Information about Novartis is available at .

Pfizer Inc discovers, develops, manufactures and markets leading prescription medicines, for humans and animals, and many of the world’s best-known consumer products. Pfizer Global Research and Development (PGRD) is the R&D division of Pfizer Inc. PGRD, the world’s largest private biomedical research organization, is headquartered in New London, Connecticut and has over 160 research projects in the following areas: antibacterials, antivirals, antifungals, arthritis, allergy and respiratory diseases, atherosclerosis, cardiovascular diseases, cancer, diabetes, gastrointestinal diseases, immunological diseases, metabolic diseases, neurodegenerative diseases, obesity, opthamological diseases, osteoporosis, pain research, psychotherapeutic research and sexual health/urology.

Additional information about Pfizer is available at .



Wyeth Pharmaceuticals is a major research-oriented pharmaceutical company with leading products in the areas of women’s health care, cardiovascular disease therapies, central nervous system drugs, musculosketetal therapies, infectious disease, hemophilia, oncology, and vaccines. As a world leader in women’s health care, the company is committed to women through ongoing research efforts and patient education programs.

Additional information about Wyeth is available at .

 

2007 Collective Membership Society Sponsors

 

Information about Amgen Inc. is available at .

 

 

Information about GSK is available at .

Nycomed is a European pharmaceutical company. Rapidly expanding, Nycomed now operates in 19 European countries including Russia / CIS. We provide hospital/specialist products throughout Europe and GP & OTC products in selected markets. Within the field of osteoporosis, Nycomed is currently partnering with NPS pharmaceuticals on the development of full-length PTH (1-84) which stimulates growth of structurally-normal bone lost to the disease. This product is expected to further strengthen Nycomed’s existing osteoporosis position built through its Nycomed Calcium & Vitamin D3 portfolio.

If you want to learn more about us please visit our website:

 

 

Home | About | Membership | BONE | Meetings | BoneKEy | Resources | IBMS Partners | Members Only

International Bone and Mineral Society (IBMS)
2025 M Street, NW, Suite 800 - Washington, DC 20036-3309 USA
Phone: (+1/202) 367-1121 Fax: (+1/202)367-2121 Email: